Georges Gemayel
Known title: DirectorCIK: 0001256088
Associated companies
Transaction History
| SUPN | ▲ Buy | Option Exercise | 7,905 | $200K | 3/6/2026 | View on chart |
| SUPN | ▼ Sell | Open Market | 8,787 | $466K | 3/6/2026 | View on chart |
| SUPN | ▼ Sell | Open Market | 10,000 | $537K | 3/5/2026 | View on chart |
| SUPN | ▲ Buy | Grant | 4,475 | $0 | 2/24/2026 | View on chart |
| SUPN | ▲ Buy | Option Exercise | 15,000 | $195K | 2/23/2026 | View on chart |
| SUPN | ▲ Buy | Grant | 5,369 | $0 | 2/22/2025 | View on chart |
| SUPN | ▲ Buy | Option Exercise | 10,787 | $124K | 11/8/2024 | View on chart |
| SUPN | ▼ Sell | Open Market | 10,787 | $392K | 11/8/2024 | View on chart |
| SUPN | ▲ Buy | Option Exercise | 14,213 | $163K | 11/7/2024 | View on chart |
| SUPN | ▼ Sell | Open Market | 14,213 | $520K | 11/7/2024 | View on chart |
| SUPN | ▼ Sell | Open Market | 3,886 | $122K | 9/13/2024 | View on chart |
| SUPN | ▲ Buy | Option Exercise | 10,000 | $115K | 9/13/2024 | View on chart |
| SUPN | ▼ Sell | Open Market | 10,000 | $313K | 9/13/2024 | View on chart |
| SUPN | ▲ Buy | Grant | 3,886 | $0 | 2/23/2024 | View on chart |
| SUPN | ▲ Buy | Grant | 3,882 | $0 | 2/22/2023 | View on chart |
| SUPN | ▲ Buy | Grant | 4,222 | $0 | 2/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Supernus mentioned in healthcare stock screening article
Supernus Pharmaceuticals was included in a recent Yahoo Finance article discussing healthcare stocks. The piece highlights specific names for investor attention while noting others to avoid, providing context for the company's current market visibility. This media coverage adds to the narrative surrounding the stock without introducing new fundamental data.
Supernus mentioned in healthcare stock screening article. Supernus Pharmaceuticals was included in a recent Yahoo Finance article discussing healthcare stocks. The piece highlights specific names for investor attention while noting others to avoid, providing context for the company's current market visibility. This media coverage adds to the narrative surrounding the stock without introducing new fundamental data.